A Case Report of Germline Compound Heterozygous Mutations in the BRCA1 Gene of an Ovarian and Breast Cancer Patient

The germline carrier of the BRCA1 pathogenic mutation has been well proven to confer an increased risk of breast and ovarian cancer. Despite BRCA1 biallelic pathogenic mutations being extremely rare, they have been reported to be embryonically lethal or to cause Fanconi anemia (FA). Here we describe a patient who was a 48-year-old female identified with biallelic pathogenic mutations of the BRCA1 gene, with no or very subtle FA-features. She was diagnosed with ovarian cancer and breast cancer at the ages of 43 and 44 and had a strong family history of breast and gynecological cancers.

[1]  L. Wiesmüller,et al.  Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia‐like phenotype, and no chromosome fragility , 2019, Molecular genetics & genomic medicine.

[2]  A. Gadducci,et al.  Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development , 2018, Front. Genet..

[3]  Joseph D. Janizek,et al.  Accurate classification of BRCA1 variants with saturation genome editing , 2018, Nature.

[4]  T. Walsh,et al.  Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1 , 2018, Proceedings of the National Academy of Sciences.

[5]  D. Zakalik,et al.  Male BRCA mutation carriers: clinical characteristics and cancer spectrum , 2018, BMC Cancer.

[6]  A. Lerário,et al.  Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients. , 2017, European journal of medical genetics.

[7]  J. Benítez,et al.  Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility , 2017, Genetics in Medicine.

[8]  M. Daly,et al.  Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study , 2016, Familial Cancer.

[9]  Martin Kircher,et al.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. , 2015, Cancer discovery.

[10]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[11]  Charis Eng,et al.  Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study , 2013, British Journal of Cancer.

[12]  Zhanhe Wu.  The concept and practice of Fanconi Anemia: from the clinical bedside to the laboratory bench. , 2013, Translational pediatrics.

[13]  A. D’Andrea.  BRCA1: a missing link in the Fanconi anemia/BRCA pathway. , 2013, Cancer discovery.

[14]  F. Couch,et al.  Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. , 2013, Cancer discovery.

[15]  P. Møller,et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers , 2012, British Journal of Cancer.

[16]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2012, Familial Cancer.

[17]  Giovanni Parmigiani,et al.  Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[18]  J. Jonkers,et al.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects , 2006, Oncogene.

[19]  Leif E. Peterson,et al.  Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. D’Andrea,et al.  The Fanconi Anemia/BRCA pathway: new faces in the crowd. , 2005, Genes & development.

[21]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[22]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[23]  C. Mathew,et al.  Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Devilee,et al.  A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage , 2001, Oncogene.

[25]  Jing Lu,et al.  Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations , 2000, Human mutation.

[26]  D. Evans,et al.  Men in breast cancer families: a preliminary qualitative study of awareness and experience. , 1998, Journal of medical genetics.

[27]  C. Liu,et al.  Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. , 1996, Genes & development.

[28]  B. Koller,et al.  Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities , 1996, Nature Genetics.

[29]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[30]  H. Silver,et al.  Fanconi syndrome; multiple congenital anomalies with hypoplastic anemia. , 1952, A.M.A. American journal of diseases of children.